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X-chromosome inactivation is widely believed to be random in early female development and to result in a mosaic
distribution of cells, approximately half with the paternally derived X chromosome inactive and half with thematernally
derived X chromosome inactive. Signiﬁcant departures from such a random pattern are hallmarks of a variety of clinical
states, including being carriers for severe X-linked diseases or X-chromosome cytogenetic abnormalities. To evaluate the
signiﬁcance of skewed patterns of X inactivation, we examined patterns of X inactivation in a population of 11,000
phenotypically unaffected females. The data demonstrate that only a very small proportion of unaffected females show
signiﬁcantly skewed inactivation, especially during the neonatal period. By comparison with this data set, the degree of
skewed inactivation in a given individual can now be quantiﬁed and evaluated for its potential clinical signiﬁcance.
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In female mammals, most genes on all X chromosomes
in excess of one per autosomal complement are silenced
epigenetically early in development, thereby making fe-
male X-chromosome gene dosage largely equivalent to
that of males.1,2 The choice of which X chromosome re-
mains active in each cell is thought to be random, so that
females have varying X-inactivation ratios, deﬁned as the
proportions of cells expressing alleles from one or the
other X chromosome. The X-inactivation ratios of females
can range from a highly skewed ratio of 0:100, where the
same X chromosome is active for all cells, to a 50:50 ratio,
where each X chromosome is active in an equal number
of cells.3 In unaffected females, the X-inactivation ratio
may be of no clinical importance, but a highly skewed X-
inactivation ratio may be indicative of carrier status for
many X-chromosome disorders, including both cytoge-
netic abnormalities and certain X-linked Mendelian con-
ditions.4–6
Skewed X-inactivation patterns may occur either as a
result of secondary cell selection during development or
by primary stochastic or genetic processes.4,7,8 The most
common reason for highly skewed X inactivation is post-
inactivation cell selection due to an X-chromosome ab-
normality that affects cell proliferation either in all cells
in the embryo or in a tissue-speciﬁc manner. For example,
females who carry balancedX;autosome translocations typ-
ically exhibit skewed X inactivation because of selection
in favor of cells in which the normal X is inactivated.9,10
X-linked disorders are generally rare in females and are
usually attributable to advantageous silencing of the X
chromosome that carries the mutant allele.5 The presump-
tion is that the initial X-inactivation choice is randombut
that, during proliferation, cells that have chosen the mu-
tant X chromosome to be active have a signiﬁcant or total
growth disadvantage and are thus underrepresented in the
adult carrier. This postinactivation cell selection has been
documented in carriers for a number of X-linkeddiseases.11–
15 In contrast to negative cell selection, the positive growth
advantage of cells in which the mutant X is primarily
active has been reported in a few conditions.16,17
It has long been recognized from a theoretical perspec-
tive that an additional explanation for nonrandom X-in-
activation ratios might include mutations in the X-inac-
tivation process itself, which causes one chromosome to
be chosen over another at the time of X inactivation in
the early embryo.8,18 Mutations in theX-inactivationpath-
way are thought to be rare, but studies of individuals with
such mutations may provide much information regarding
the regulation of the X-inactivation pathway. Studies of
large families19,20 and females who express X-linked dis-
orders18 have revealed that a locus or loci on the X chro-
mosome can affect the X-inactivation ratio. Studies of fe-
males with Duchenne muscular dystrophy (MIM 300377)
also suggest that other modifying loci exist that affect the
X-inactivation ratio.21,22 These limited studies of human
families are intriguing, since the X-inactivation ratio is
known to be under primary genetic control in themouse.23–
25 The major locus controlling the preferential choice of
which X chromosome is to remain active in the mouse is
the X-linked X-controlling element (Xce) locus, although
the mechanism responsible for this effect remains elusive.
It has been suggested that similar XCE alleles might exist
in the human population.19
Whereas the probability that highly skewed X-inactiva-
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tion ratios occur by chance may be low,3 an accurate as-
sessment of the X-inactivation variance is needed to quan-
tify this probability. With a highly accurate measurement
of X-inactivation in a large population, the number of cells
present in the embryo when the choice of which X re-
mains active can be determined.26 Previous studies to de-
termine this number used distributions of X-inactivation
ratios from apparently unaffected adult females.26–28 How-
ever, since skewing increases with age in unaffected adult
and elderly females,29–32 use of these distributions to pre-
dict stem-cell number may not be appropriate, since the
predicted stem-cell number is inversely proportional to
the distribution variance.26 In addition, any errors in de-
termining the X-inactivation ratio, likely dependent on
the particular assay being used, would inﬂuence and likely
increase the apparent variance.
X-inactivation ratios have been determined with a va-
riety of assays that rely on the differential expression of
polymorphic X-linked genes or, less directly, on the dif-
ferential methylation of sequences on the active and in-
active chromosomes.26,28,29,33–35 Because of its high poly-
morphism content, the most commonly used assay ex-
amines differential methylation of the human androgen
receptor (AR) gene.28 Although the assay has been used in
many studies, a wide range of results has been reported
with respect to the distribution of X-inactivation ratios in
the population(s) under study,18,20,28,32,36–39 with as many
as 20%–30% of the population reported to show highly
skewed ratios. Although this presumably reﬂects, in part,
the relatively small control groups reported, it may also
reﬂect assay variation; reproducibility, in particular, is a
key parameter for an assay that is highly sensitive topartial
restriction-enzyme digestion and to potential PCR quan-
titation or electrophoresis artifacts.
A deﬁnitive data set of X-inactivation ratios in a large
sample of phenotypically unaffected females from the gen-
eral population would be useful as a baseline for studies
of X inactivation in various patient populations and/or
genetically deﬁned cohorts. Toward this goal, we have de-
termined the distribution of X-inactivation patterns in
blood samples from 11,000 newborn infants and adult
women, using the ARX-inactivation assay. The results pro-
vide a comprehensive estimate of the frequency of indi-
viduals in the general population with highly skewed X-
inactivation ratios and suggest that screening of the new-
born female population may be an effective means of as-




A total of 1,284 anonymized DNA samples from either adult pe-
ripheral or newborn cord bloodwere obtained from several sources.
All samples were obtained from phenotypically unaffected in-
dividuals from the general control population or from family
studies in which it was determined that the individuals did not
carry the speciﬁc defect in question. The racial and ethnic com-
position of the sample population was mixed. The following fe-
male samples were tested: 127 from the general adult population
of Cleveland (provided by Drs. Stuart Schwartz and GeorgiaWies-
ner, Case Western Reserve University), 77 from Botnia, Finland40
(provided by Drs. Melanie Mahtani and Eric Lander), 106 from
a Mennonite group in western Pennsylvania (provided by Dr. Eric
Puffenberger), 105 from Ashkenazi Jewish mothers with normal
pregnancies (provided by Dr. David Gurwitz, National Laboratory
for the Genetics of Israeli Populations, Sackler Faculty of Medi-
cine, Tel Aviv University, Tel Aviv). The remaining blood samples
were from newborn cord or from mothers of newborns from a
six-county area in the upper Savannah region of South Carolina.
All samples were obtained with approval from the respective in-
stitutions and were fully anonymized before transfer to Case
Western Reserve University for X-inactivation analysis.
Determination of X-Inactivation Patterns
To determine the X-inactivation pattern, we examined the meth-
ylation status of the AR locus, as described elsewhere.18 Brieﬂy,
∼50–150 ng of DNA was digested in duplicate for 16 h either with
HpaII plus RsaI or with RsaI alone as a control. In addition, digests
with HhaI and RsaI, as well as CfoI and RsaI, were run on a select
number of samples to test the accuracy of the assay. After diges-
tion, the enzymes were inactivated at 80C for 20 min, and one-
tenth of the resulting digest was used for PCR ampliﬁcation as
described elsewhere.18 The resulting products were run on an ABI
373A automated sequencer or an ABI 3100 genetic analyzer and
were analyzed by GeneScan software (Applied Biosystems). The
raw peak height values of the digested samples were corrected for
ampliﬁcation efﬁciency by using the average of the two samples
digested with RsaI alone (a restriction enzyme with sites outside
the PCR product, which is not sensitive to methylation and thus
digests active and inactive X alleles equally). The X-inactivation
pattern (expressed arbitrarily as a ratio of the smaller:larger allele)
is the resulting corrected average of the duplicate samples di-
gested with HhaI and RsaI. Samples were scored only if the two
alleles were separated by more than two CAG repeats, to avoid
uncertain contributions of one peak to the other. In addition,
one control male sample and one sample from a female known
from an earlier study18 to have a completely nonrandom pattern
of X inactivation (198:2) were included in every batch of samples,
to control for complete digestion and ampliﬁcation efﬁciency.
Expression-Based X-Inactivation Assay
Transformed lymphoblast cell lines were grown and harvested for
DNA and RNA, as described elsewhere.35 RNA was isolated with
the Stratagene Strataprep Total RNA Miniprep Kit. cDNA was pre-
pared by using plus and minus reverse-transcriptase reactions, to
control for DNA contamination. The resulting cDNA was PCR-
ampliﬁed with primers designed to detect an HinfI restriction-
enzyme polymorphism in exon 6 of the XIST gene, followed by
a single extension reaction with a ﬂuorescently labeled primer.35
The resulting product was digested with HinfI for at least 4 h at
37C, and the products were run on an ABI 373A automated se-
quencer. Peak height values of the resulting raw data were ana-
lyzed with GeneScan software, as described above. Control sam-
ples for complete digestion of the ampliﬁed products were in-
cluded for every gel.
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Figure 1. The X-inactivation patterns of 1,005 females were as-
signed to 21 “bins” with a range of !2:98 to 198:2, with incre-
ments of 5%. These are normally distributed, with the mean of
the distribution residing at 49:51 and the median at 50:50 (SD
of the mean p 17).
Results
Technical Considerations
Because of the variability in the reports of distribution of
X-inactivation patterns determined by use of the AR assay,
we examined some of the variables that might inﬂuence
the apparent results. We began by addressing whichmeth-
ylation-sensitive restriction enzyme yielded themost-con-
sistent and reproducible results for us. Triplicate samples
were assayed by using the restriction enzyme RsaI in con-
junction with a methylation-sensitive restriction enzyme—
HpaII, HhaI, or CfoI (an isoschizomer of HhaI), each of
which has sites within the AR PCR product—as well as a
mock-digested control with use of RsaI alone. HpaII and
HhaI results were highly correlated with each other, but
CfoI consistently generated more variable results (110%
variance). On further investigation, CfoI was found to be
only partially heat-inactivated (Boehringer Mannheim and
Gibco BRL) and could be completely inactivated only after
phenol/chloroform extraction. Presumably, the resulting
digested product continued to be digested during PCR am-
pliﬁcation and yielded muchmore variable results between
duplicates. To increase the level of precision and accuracy
in this data set, we therefore used only HpaII as the meth-
ylation-sensitive restriction enzyme, in conjunction with
RsaI for data generation. Reproducibility of the data set
was conﬁrmed by assaying all samples in duplicate and
by reassaying 120 samples chosen at random with HhaI
as themethylation-sensitive enzyme (for pairedHpaII- and
HhaI-digested samples, [Student’s t test];P 1 .1 rp 0.97
[Pearson correlation coefﬁcient]).
To determine, in a quantitative manner, whether the X-
inactivation patterns measured indirectly at the AR locus
correlate with X-inactivation patterns determined directly
by gene expression, we also examined a transcribed poly-
morphism at the XIST locus. Since XIST is expressed ex-
clusively from the inactive X chromosome in female so-
matic cells,41 this provides a direct estimate of the propor-
tion of cells carrying a particularXIST allele on the inactive
X chromosome.35 We determined the X-inactivation pat-
terns of 18 polyclonal lymphoblast cell lines informative
at both the AR and XIST loci, using both assays. Because
the phase of the AR and XIST alleles was not known, we
used a best-ﬁt model to correlate the data. Whereas such
a model is insensitive to allelic phase at X-inactivation
patterns near 50:50, it is highly sensitive at more-extreme
patterns, as frequently observed in clonal or oligoclonal
lymphoblast lines.35 On the basis of this model, X-inac-
tivation patterns determined by the AR methylation assay
were highly correlated with those determined directly by
XIST expression ( ), which indicates that the AR2R p 0.969
assay is an accurate measure of X inactivation (data not
shown).
Notwithstanding the apparent robustness of the assay,
we do note what appears to be a modest shift toward the
left in the X-inactivation distributions (see, e.g., ﬁg. 1),
consistent with a slight bias toward ampliﬁcation of the
smaller AR allele. This may reﬂect a slight overcorrection
when the RsaI digest is used; nonetheless, this shift is not
statistically signiﬁcant and has not been explored further.
Distribution of X-Inactivation Patterns in 1,005 Samples
from Female Subjects
The principal advantage of the AR assay for measuring X-
inactivation patterns is the high heterozygosity of a (CAG)n
polymorphism near the 5′ end.28 Indeed, only ∼8% of the
1,284 samples were uninformative for this polymorphism
and were thus excluded from the study. However, because
of the stutter bands frequently observed in minisatellite
repeats and to avoid potential artifacts thatmight interfere
with quantitation, we also rejected any heterozygous sam-
ples in which the stutter band from the larger allele over-
lapped the primary band of the lower allele. This resulted
in the elimination of an additional 13% of the original
samples.
On the basis of these criteria, DNA samples from 1,005
females who were informative for the AR polymorphism
were analyzed for their X-inactivation patterns (ﬁg. 1). In
the resulting data set, 25% of the samples had X-inacti-
vation patterns skewed to the extent of 170:30 or !30:70;
only 8% of the samples were skewed to the extent of 180:
20 or !20:80 (table 1). We further examined the distribu-
tion by dividing the data set by population groups (see
the “Material and Methods” section); there were no sta-
tistical differences between the means of any of the dis-
tributions. However, there was a highly signiﬁcant differ-
ence between variances ( [F test]) when the new-Pp .0008
born population was compared with the remaining group
of samples (mostly adult women of child-bearing age and
a small number of young adults aged 113 years) (ﬁg. 2).
This ﬁnding is consistent with previous suggestions based
on a limited number of samples that indicated a higher
proportion of skewed samples in older females.30,32,37,42,43
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Figure 2. Distributions of X-inactivation ratios of both newborn
samples ( ) and unaffected adult females ( ).np 590 np 415
Table 1. Comparison of Skewed X-Inactivation Ratios in Newborn and Adult
Populations
Population n Mean SD
Percentage of Population with
X-Inactivation Ratio of
!20:80/180:20 !10:90/190:10 !5:95/195:5
Newborns 590 50:50 15.4 4.9 .5 .2
Adults 415 48:52 19.3 14.2 3.6 1.7
Total 1,005 49:51 17.2 8.8 1.8 .8
This effect may reﬂect random ﬂuctuation in the hema-
topoietic cell population over time or the possible ascer-
tainment of a small proportion of phenotypically unaf-
fected females in whom postinactivation cell selectionhas
skewed the cell population in favor of one allele on the
active X.
Estimate of the Number of Stem Cells at the Time of X
Inactivation
Previous studies determined the number of hematopoietic
stem cells present at the time of X-inactivation choice by
use of the variance of the X inactivation–pattern distribu-
tion.26 To estimate the primordial stem-cell pool size (N),
the formula for the variance of a binomial distribution
was used ( ) and setting the probabilityvariancep pq/N
that either allele (p or q) is active to 0.5. Normal distri-
butions were drawn by determining the variance (j2) for
each of the values of N and drawing the curve with use
of the equation for the normal distribution (ﬁg. 3). To limit
the potential effect that somatic mutations and environ-
mental factors might impose on hematopoietic stem cells,
we performed these calculations using only the 590 new-
born samples. With the SD of 15.3%, the number of stem
cells is predicted to be between 8 and 16, which is con-
sistent with previous estimates26,27,42 (ﬁg. 3).
Discussion
The distribution of X-inactivation patterns in phenotyp-
ically unaffected females has been reported in a number
of previous studies that used the AR polymorphism as-
say.14,15,18,20,28,32,37,39,44 We believe that our data set, which
was based on a large number of individuals and for which
we used a robust assay subjected to rigorous validation,
provides an accurate proﬁle of X-inactivation patterns in
the general female population. The distribution reported
here thus establishes a set of baseline data for comparing
patterns in various patient populations and/or genetically
stratiﬁed study populations. We attempted to limit over-
or underestimating the proportion of individuals who ex-
hibit highly skewed patterns of X inactivation (i.e., more
extreme than 80:20 or 90:10, which are the threshold
values adopted in many studies) by controlling for a num-
ber of potential technical complications, such as incom-
plete enzyme digestion or scoring of alleles that differ by
only a single repeat unit. The reasonable accuracy of our
distribution is supported by the fact that the X-inactiva-
tion patterns determined by the AR differential methyla-
tion assay are highly correlated with those determined
more directly by assay of X-linked gene expression (data
not shown). Any systematic problems with the AR assay
would presumably have reduced the correlation to an un-
acceptable level.
Nonetheless, it is important to acknowledge that the
current study has several limitations. First, the reported
distribution is based on methylation analysis, an indirect
assessment of X-inactivation status. Although AR meth-
ylation does correlate with allele-speciﬁc expression of at
least one X-linked locus (XIST), an extension of this study
could examine the increasing number of other expressed
polymorphisms now amenable to analysis.2 Second, the
current analysis was performed on only cord or peripheral
blood samples. Although this is also true of most other X-
inactivation studies performed elsewhere, it is conceivable
that X-inactivation patterns will vary somewhat in differ-
ent clinically relevant tissues.
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Figure 3. Comparison of the newborn distribution with predicted normal distributions of varying stem-cell pool size. The solid black
curve follows a normal distribution with use of the actual SD of the newborn samples (15.4 [ﬁg. 2]). The estimated number of precursor
stem cells predicted by the newborn SD is between 10 and 12 cells.
These limitations notwithstanding, our data support pre-
vious observations that, with advancing age, there is greater
variation in X inactivation–ratio distribution. The relative
paucity of skewed ratios (table 1), however, argues that
skewing, when present, may be more clinically informa-
tive than previously suspected, especially in newborns.
Because !5% of newborn samples show patterns of skew-
ing of !20% or 180%, any newborn who exhibits skewing
at birth may warrant further genetic evaluation, on the
basis of statistical considerations alone. Because of the
blinding of the samples, we were unable to go back and
examine the highly skewed samples for chromosomal ab-
normalities and/or history of X-linked disease; however,
such a prospective study might now be appropriate.
The most striking revelation is that very few samples in
our study were highly skewed, with only a few newborn
samples exhibiting 195:5% X-inactivation ratios. How-
ever, we believe we have ruled out partial digestion as the
cause of the paucity of skewed samples, because we can
digest with a different enzyme or with double digests and
get highly reproducible results. Further, the number of
skewed samples we observed is similar to that predicted
by using the determined variance in the normal distribu-
tion equation. On the basis of this evidence, we believe
it is highly noteworthy that so few females exhibit skewed
X-inactivation ratios, at least in the tissue sampled.
Also noteworthy is the fact that the distribution was
platykurtic, with a kurtosis value of 0.26. If there were
extensive partial digestion, the distribution would have a
decreased variance about the mean, withmore of the sam-
ples residing at or near 50:50, which would result in pos-
itive kurtosis. The negative value that we observe suggests
that what we are observing is not partial digestion of the
DNA but, rather, that there are multiple overlapping dis-
tributions with smaller SDs with different means. This is
statistical evidence for the suggestion that there may be
a genetic locus (or loci) that affects the determination of
which X chromosome will remain active in the cell. This
locus (loci) is not likely to be closely linked to theAR locus,
since we do not see a directionality to the skewing (re-
ﬂected in a change of the mean); rather, we see a broaden-
ing of the spread of the distribution or a decrease in the
kurtosis of the curve.
The data in table 1 provide a basis for evaluating the
presence of skewed X-inactivation patterns in various clin-
ical populations. Highly skewed inactivation patterns have
been described in carriers of several X-linked disorders5,6,8—
most notably, various X-linked mental retardation condi-
tions15 and X-linked immune disorders.45 The unusual na-
ture of skewing in carriers of such defects can now be
quantiﬁed, in both newborn and adult age groups.
Given the rarity of highly skewed X inactivation in both
populations, particularly among newborns, a ﬁnding of
skewed inactivation as extreme as 90:10 or 95:5 deserves
increased scrutiny, since it is, a priori, such an unlikely
event (table 1). The application of Bayesian statistics may
allow quantiﬁcation of the level of suspicion that might
be appropriate. For example, in a family with an X-linked
condition known to be characterized by highly skewed
patterns of inactivation, the ﬁnding of such a pattern in
a newborn potential carrier would be much more likely
to be due to her being a carrier than to chance alone
(posterior odds ratio ∼100:1). A corollary of this would be
that, even in the general population (in which one might
estimate the overall frequency of X-linked disease to be,
at most, 1%), a ﬁnding of highly skewed inactivation is
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at least as likely to be explained by being a carrier for an
X-linked trait that affects X-inactivation ratios as by chance
alone. Thus, even in the general population (and, again,
especially in the newborn population), a ﬁnding of skewed
inactivation should prompt questions about possible fam-
ily histories consistent with a potential X-linked condition
(e.g., a history of miscarriage, a deﬁcit of live male births,
or idiopathic mental retardation in amale familymember).
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